A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer

BACKGROUND: This phase 1 clinical trial was conducted to determine the safety, maximum-tolerated dose (MTD), and pharmacokinetics of imatinib, bevacizumab, and metronomic cyclophosphamide in patients with advanced colorectal cancer (CRC). METHODS: Patients with refractory stage IV CRC were treated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelley, R K, Hwang, J, Magbanua, M J M, Watt, L, Beumer, J H, Christner, S M, Baruchel, S, Wu, B, Fong, L, Yeh, B M, Moore, A P, Ko, A H, Korn, W M, Rajpal, S, Park, J W, Tempero, M A, Venook, A P, Bergsland, E K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790192/
https://www.ncbi.nlm.nih.gov/pubmed/24022191
http://dx.doi.org/10.1038/bjc.2013.553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790192/
https://www.ncbi.nlm.nih.gov/pubmed/24022191
http://dx.doi.org/10.1038/bjc.2013.553

Ejemplares similares